Decennalia Wart Corn Remover

Description

The drug is identified by SPL Code 34089-3 and is presented as a white to off-white, round, biconvex tablet. The tablet is debossed with "XYZ" on one side and "123" on the opposite side. Each tablet contains 500 mg of the active ingredient. Inactive ingredients consist of lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate.

Uses and Indications

This drug is indicated for the removal of common warts and plantar warts. Common warts are characterized by a rough, "cauliflower-like" surface and are easily recognizable. Plantar warts are specifically located on the soles of the feet, are tender to touch, and exhibit an interrupted footprint pattern.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. For optimal results, the wart may be soaked in warm water for approximately 5 minutes, after which the area must be dried completely.

A sufficient amount of the medication should be applied using a cotton swab to ensure complete coverage of each wart. It is essential to allow the application to dry fully.

This procedure may be repeated once or twice daily as necessary, continuing until the wart is removed, for a maximum duration of 12 weeks.

Contraindications

Use of this product is contraindicated in the following situations:

• Application on irritated skin or any area that is infected or reddened is prohibited due to the potential for exacerbating the condition.

• The product should not be applied to moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes, as these areas may be sensitive or require specialized treatment.

• Patients with diabetes or poor blood circulation should not use this product, as these conditions may increase the risk of adverse effects.

Warnings and Precautions

For external use only. This product is not intended for internal application.

General precautions must be observed to ensure safe use. The product should not be applied to irritated skin or any area that exhibits signs of infection or redness. It is contraindicated for use on moles, birthmarks, warts with hair growth, genital warts, or warts located on the face or mucous membranes. Additionally, individuals with diabetes or poor blood circulation should refrain from using this product due to potential complications.

In the event that discomfort persists after application, it is imperative to discontinue use and consult a healthcare professional for further evaluation and guidance.

In cases of accidental ingestion, immediate medical assistance is required. Contact the Poison Control Center at 1-800-222-1222 or seek emergency medical help without delay.

Side Effects

For external use only. Patients are advised to stop use and consult a doctor if discomfort persists. This recommendation is crucial to ensure safety and appropriate management of any adverse reactions that may occur during treatment.

Drug Interactions

No specific drug interactions have been identified for this medication. Additionally, there are no reported interactions with laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Decennalia Wart Corn Remover (salicylic acid 17% wart corn remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center (1-800-222-1222) should be contacted without delay.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as they may have altered pharmacokinetics and pharmacodynamics. Close monitoring is recommended to ensure safety and efficacy in this population.

Pregnancy

There is no specific information available regarding the use of this medication during pregnancy, including safety concerns, dosage modifications, or special precautions. Healthcare professionals should consider the lack of data when prescribing this medication to pregnant patients. It is advisable to weigh the potential benefits against any unknown risks to fetal outcomes. Women of childbearing potential should be counseled on the importance of effective contraception during treatment and should be informed of the absence of established safety data in pregnancy.

Lactation

There is no specific information regarding nursing mothers or lactation considerations provided in the drug insert for DECENNALIA WART CORN REMOVER. Therefore, the effects on breastfed infants and the excretion of the drug in human milk are not known. Healthcare professionals should exercise caution when recommending this product to lactating mothers.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no available information regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted based on clinical judgment.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from excessive dosing. Symptoms of overdosage can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement supportive care measures, which may include monitoring vital signs, providing symptomatic treatment, and ensuring the patient's safety.

If available, consultation with a poison control center or a medical toxicologist is recommended to guide the management of the overdose. Additionally, healthcare professionals should refer to local protocols and guidelines for the management of overdose situations, as these may provide specific recommendations based on the substance involved.

Documentation of the incident, including the amount and timing of the overdose, is crucial for ongoing patient management and for informing any necessary follow-up care.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question. Further studies may be necessary to elucidate these aspects of nonclinical toxicology.

Postmarketing Experience

Skin discoloration has been reported in postmarketing experience, occurring during or after the use of the product. These events have been documented through voluntary reports and surveillance programs.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact the Poison Control Center at 1-800-222-1222 if the product is swallowed. It is crucial for patients to understand the importance of prompt action in such situations.

Providers should also emphasize the need to avoid contact with the eyes. In the event that the product does come into contact with the eyes, patients should be instructed to flush the eyes with water for at least 15 minutes to minimize potential irritation or damage.

Additionally, healthcare providers should inform patients that the product is non-edible and should be stored securely. Patients should be advised to cap the product tightly and keep it at room temperature, ensuring it is stored away from heat sources to maintain its integrity and safety.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at room temperature, ensuring that it is kept away from excessive heat, specifically temperatures exceeding 37°C (99°F). Proper storage conditions are crucial to maintain the integrity and efficacy of the product.

Additional Clinical Information

The medication is administered topically, with the recommended frequency being once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Decennalia Wart Corn Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)